Summary:
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 50+. No placebo,
Qualified Participants Must:
Participate in the study for 12 months
Qualified Participants May Receive:
Compensation for all visitis and diaries